Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Контрацепция и фолаты: новые возможности профилактики и лечения
Контрацепция и фолаты: новые возможности профилактики и лечения
Прилепская В.Н., Назаренко Е.Г. Контрацепция и фолаты: новые возможности профилактики и лечения. Гинекология. 2018; 20 (1): 47–49.
DOI: 10.26442/2079-5696_20.1.47-49
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье отражены последние сведения о новых контрацептивных препаратах, содержащих фолиевую кислоту в виде левомефолата кальция, которые кроме контрацептивных свойств обладают новыми возможностями как для подготовки к будущей беременности и профилактики пороков развития нервной трубки у плода, так и для лечения косметических дефектов, таких как акне вульгарис легкой и средней тяжести, депрессивных расстройств, задержки жидкости в организме.
Ключевые слова: контрацепция, фолаты, беременность, пороки развития плода.
Key words: contraception, folates, pregnancy, fetal malformations.
Ключевые слова: контрацепция, фолаты, беременность, пороки развития плода.
________________________________________________
Key words: contraception, folates, pregnancy, fetal malformations.
Полный текст
Список литературы
1. Корсуновская И.М., Дворянкова Е.В. Преимущества терапии акне оральными контрацептивами. Мед. совет. 2017; 11: 3–6. / Korsunovskaia I.M., Dvoriankova E.V. Preimushchestva terapii akne oralnymi kontratseptivami. Med. sovet. 2017; 11: 3–6. [in Russian]
2. Самцов А.В. Клинические особенности течения акне у женщин. Вестн. дерматологии и венерологии. 2012; 6: 60–2. / Samtsov A.V. Klinicheskie osobennosti techeniia akne u zhenshchin. Vestn. dermatologii i venerologii. 2012; 6: 60–2. [in Russian]
3. Thiboutot D. Overview of acne and its treatment. Cutis 2008; 81 (S1): 3–7.
4. Монахов С.А. Фолатсодержащие антиандрогенные оральные контрацептивы: дерматологические аспекты. Гинекология. 2016; 18 (4): 54–8. / Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 54–8. [in Russian]
5. Кузнецова И.В., Коновалов В.А. Фолиевая кислота и ее роль в женской репродукции. Гинекология. 2014; 16 (4): 17–23. / Kuznetsova I.V., Konovalov V.A. Folic acid and its role in female reproduction. Gynecology. 2014; 16 (4): 17–23. [in Russian]
6. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.
7. Радзинский В.Е., Рябинкина Т.С., Раевская О.А. Прием синтетических фолатов: за и против. StatusPraesens. 2017; 5 (42). / Radzinskii V.E., Riabinkina T.S., Raevskaia O.A. Priem sinteticheskikh folatov: za i protiv. StatusPraesens. 2017; 5 (42). [in Russian]
8. Wang ZM, Zhou B, Nie ZL et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2012; 22 (10): 890–9.
9. Peng Y, Dong B, Wang Z. Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: A cohort study based on 1999–2010 National health and nutrition examination survey (NHANES). Int J Cardiol 2016; 219: 136–42.
10. Schroecksnadel K, Frick B, Fiegl M et al. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007; 45 (1): 47–53.
11. Tavani A, Malerba S, Pelucchi C et al. Diatary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
12. Ginsburg HJ, Mendez RV, Haskar-Zolnierek KB. Cautionaryote about magnitude of decline in neural tube birth defects following folic acid fortification in the United States. Int J Vitam Nutr Res 2017; р. 1–3.
13. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’srole. Adv Nutr 2012; 3 (1): 21–38.
14. Ahmed T, Fellus I, Gaudet J et al. Effect of folic acid on human trophoblast health and function in vitro. Placenta 2016; 37: 7–15.
15. Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57 (5): 142–9.
16. Practice Bulletin №187 Summary: neural tube defects. Obstet Gynecol 2017; 130 (6): 1394–6.
17. Демикова Н.С., Лапина А.С., Подольная М.А. и др. Динамика частоты врожденных пороков развития в РФ (по данным федеральной базы мониторинга ВПР за 2006–2012 гг.). Рос. вестн. перинатологии и педиатрии. 2015; 2: 72–7. / Demikova N.S., Lapina A.S., Podolnaia M.A. i dr. Dinamika chastoty vrozhdennykh porokov razvitiia v RF (po dannym federalnoi bazy monitoringa VPR za 2006–2012 gg.). Ros. vestn. perinatologii i pediatrii. 2015; 2: 72–7. [in Russian]
18. Wilson RD, Genetics Committee, Special Contributors. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Can 2015; 37 (6): 534–52.
19. Прегравидарная подготовка. Клинический протокол. Авт.-разраб. В.Е.Радзинский и др. М.: StatusPraesens, 2016. / Pregravidarnaia podgotovka. Klinicheskii protokol. Avt.-razrab. V.E.Radzinskii i dr. M.: StatusPraesens, 2016. [in Russian]
20. Громова О.А., Торшин И.Ю., Тетруашвили Н.К., Лисицына Е.Ю. Систематический анализ взаимосвязи дефицита витаминов и врожденных пороков развития. Consilium Medicum. 2012; 4 (6): 34–40. / Gromova O.A., Torshin I.Iu., Tetruashvili N.K., Lisitsyna E.Iu. Sistematicheskii analiz vzaimosviazi defitsita vitaminov i vrozhdennykh porokov razvitiia. Consilium Medicum. 2012; 4 (6): 34–40. [in Russian]
21. Shere M, Bapat P, Nickel C et al. Association between use of oral contraceptives and folate status: a systematic review and meta-analysis. J Obstet Gynaecol Can 2015; 37 (5): 430–8.
22. Michels KA, Wactawski-Wende J, Mills JL et al. Folate, homocysteine and the ovarian cycle among healthy regularly menstruating women. Hum Reprod 2017; 32 (8): 1743–50.
23. Micle O, Muresan M, Antal L et al. The influence of homocysteine and oxidative stress on pregnancy outcome. J Med Life 2012; 5 (1): 68–73.
24. Kim MW, Hong SC, Choi JS et al. Homocysteine, folate and pregnancy outcomes. J Obstet Gynaecol 2012; 32 (6): 520–4.
25. Gomes S, Lopes C, Pinto E. Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHO. Public Health Nutr 2016; 19 (1): 176–89.
26. Cawley S, McCartney D, Woodside JV et al. Optimization of folic acid supplementation in the prevention of neural tube defects. J Public Health (Oxf) 2017; р. 1–8.
27. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International active surveillance study of women taking oral contraceptives. Contraception 2014; 89 (4): 253–63.
28. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7.
29. Кулаков В.И., Прилепская В.Н., Радзинский В.Е. и соавт. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. М.: ГЭОТАР-Медиа, 2007. / Kulakov V.I., Prilepskaia V.N., Radzinskii V.E. i soavt. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. M.: GEOTAR-Media, 2007. [in Russian]
30. Юренева С.В., Прилепская В.Н., Ледина А.В. Предменструальный синдром и предменструальное дисфорическое расстройство. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. 3-е изд., перераб. М.: ГЭОТАР-Медиа, 2016; с. 895–907. / Iureneva S.V., Prilepskaia V.N., Ledina A.V. Predmenstrual'nyi sindrom i predmenstrual'noe disforicheskoe rasstroistvo. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. 3-e izd., pererab. M.: GEOTAR-Media, 2016; s. 895–907. [in Russian]
31. Тапильская Н.И., Глушакова Р.И. Пролонгированный режим комбинированного орального контрацептива: фокус на профилактику воспалительных заболеваний органов малого таза. Гинекология. 2017; 19 (1): 2–7. / Tapilskaia N.I., Glushakova R.I. Prolonged treatment of combined oral contraceptive: a focus on the prevention of inflammatory diseases of the pelvic organs. Gynecology. 2017; 19 (1): 2–7. [in Russian]
32. Касян В.Н. Комбинированные гормональные контрацептивы с фолатами: преимущество в лечении акне. Акушерство и гинекология. 2017; 10. / Kasian V.N. Kombinirovannye gormonalnye kontratseptivy s folatami: preimushchestvo v lechenii akne. Akusherstvo i ginekologiia. 2017; 10. [in Russian]
2. Samtsov A.V. Klinicheskie osobennosti techeniia akne u zhenshchin. Vestn. dermatologii i venerologii. 2012; 6: 60–2. [in Russian]
3. Thiboutot D. Overview of acne and its treatment. Cutis 2008; 81 (S1): 3–7.
4. Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 54–8. [in Russian]
5. Kuznetsova I.V., Konovalov V.A. Folic acid and its role in female reproduction. Gynecology. 2014; 16 (4): 17–23. [in Russian]
6. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.
7. Radzinskii V.E., Riabinkina T.S., Raevskaia O.A. Priem sinteticheskikh folatov: za i protiv. StatusPraesens. 2017; 5 (42). [in Russian]
8. Wang ZM, Zhou B, Nie ZL et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2012; 22 (10): 890–9.
9. Peng Y, Dong B, Wang Z. Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: A cohort study based on 1999–2010 National health and nutrition examination survey (NHANES). Int J Cardiol 2016; 219: 136–42.
10. Schroecksnadel K, Frick B, Fiegl M et al. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007; 45 (1): 47–53.
11. Tavani A, Malerba S, Pelucchi C et al. Diatary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
12. Ginsburg HJ, Mendez RV, Haskar-Zolnierek KB. Cautionaryote about magnitude of decline in neural tube birth defects following folic acid fortification in the United States. Int J Vitam Nutr Res 2017; р. 1–3.
13. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’srole. Adv Nutr 2012; 3 (1): 21–38.
14. Ahmed T, Fellus I, Gaudet J et al. Effect of folic acid on human trophoblast health and function in vitro. Placenta 2016; 37: 7–15.
15. Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57 (5): 142–9.
16. Practice Bulletin №187 Summary: neural tube defects. Obstet Gynecol 2017; 130 (6): 1394–6.
17. Demikova N.S., Lapina A.S., Podolnaia M.A. i dr. Dinamika chastoty vrozhdennykh porokov razvitiia v RF (po dannym federalnoi bazy monitoringa VPR za 2006–2012 gg.). Ros. vestn. perinatologii i pediatrii. 2015; 2: 72–7. [in Russian]
18. Wilson RD, Genetics Committee, Special Contributors. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Can 2015; 37 (6): 534–52.
19. Pregravidarnaia podgotovka. Klinicheskii protokol. Avt.-razrab. V.E.Radzinskii i dr. M.: StatusPraesens, 2016. [in Russian]
20. Gromova O.A., Torshin I.Iu., Tetruashvili N.K., Lisitsyna E.Iu. Sistematicheskii analiz vzaimosviazi defitsita vitaminov i vrozhdennykh porokov razvitiia. Consilium Medicum. 2012; 4 (6): 34–40. [in Russian]
21. Shere M, Bapat P, Nickel C et al. Association between use of oral contraceptives and folate status: a systematic review and meta-analysis. J Obstet Gynaecol Can 2015; 37 (5): 430–8.
22. Michels KA, Wactawski-Wende J, Mills JL et al. Folate, homocysteine and the ovarian cycle among healthy regularly menstruating women. Hum Reprod 2017; 32 (8): 1743–50.
23. Micle O, Muresan M, Antal L et al. The influence of homocysteine and oxidative stress on pregnancy outcome. J Med Life 2012; 5 (1): 68–73.
24. Kim MW, Hong SC, Choi JS et al. Homocysteine, folate and pregnancy outcomes. J Obstet Gynaecol 2012; 32 (6): 520–4.
25. Gomes S, Lopes C, Pinto E. Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHO. Public Health Nutr 2016; 19 (1): 176–89.
26. Cawley S, McCartney D, Woodside JV et al. Optimization of folic acid supplementation in the prevention of neural tube defects. J Public Health (Oxf) 2017; р. 1–8.
27. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International active surveillance study of women taking oral contraceptives. Contraception 2014; 89 (4): 253–63.
28. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7.
29. Kulakov V.I., Prilepskaia V.N., Radzinskii V.E. i soavt. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. M.: GEOTAR-Media, 2007. [in Russian]
30. Iureneva S.V., Prilepskaia V.N., Ledina A.V. Predmenstrual'nyi sindrom i predmenstrual'noe disforicheskoe rasstroistvo. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. 3-e izd., pererab. M.: GEOTAR-Media, 2016; s. 895–907. [in Russian]
31. Tapilskaia N.I., Glushakova R.I. Prolonged treatment of combined oral contraceptive: a focus on the prevention of inflammatory diseases of the pelvic organs. Gynecology. 2017; 19 (1): 2–7. [in Russian]
32. Kasian V.N. Kombinirovannye gormonalnye kontratseptivy s folatami: preimushchestvo v lechenii akne. Akusherstvo i ginekologiia. 2017; 10. [in Russian]
2. Самцов А.В. Клинические особенности течения акне у женщин. Вестн. дерматологии и венерологии. 2012; 6: 60–2. / Samtsov A.V. Klinicheskie osobennosti techeniia akne u zhenshchin. Vestn. dermatologii i venerologii. 2012; 6: 60–2. [in Russian]
3. Thiboutot D. Overview of acne and its treatment. Cutis 2008; 81 (S1): 3–7.
4. Монахов С.А. Фолатсодержащие антиандрогенные оральные контрацептивы: дерматологические аспекты. Гинекология. 2016; 18 (4): 54–8. / Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 54–8. [in Russian]
5. Кузнецова И.В., Коновалов В.А. Фолиевая кислота и ее роль в женской репродукции. Гинекология. 2014; 16 (4): 17–23. / Kuznetsova I.V., Konovalov V.A. Folic acid and its role in female reproduction. Gynecology. 2014; 16 (4): 17–23. [in Russian]
6. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.
7. Радзинский В.Е., Рябинкина Т.С., Раевская О.А. Прием синтетических фолатов: за и против. StatusPraesens. 2017; 5 (42). / Radzinskii V.E., Riabinkina T.S., Raevskaia O.A. Priem sinteticheskikh folatov: za i protiv. StatusPraesens. 2017; 5 (42). [in Russian]
8. Wang ZM, Zhou B, Nie ZL et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2012; 22 (10): 890–9.
9. Peng Y, Dong B, Wang Z. Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: A cohort study based on 1999–2010 National health and nutrition examination survey (NHANES). Int J Cardiol 2016; 219: 136–42.
10. Schroecksnadel K, Frick B, Fiegl M et al. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007; 45 (1): 47–53.
11. Tavani A, Malerba S, Pelucchi C et al. Diatary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
12. Ginsburg HJ, Mendez RV, Haskar-Zolnierek KB. Cautionaryote about magnitude of decline in neural tube birth defects following folic acid fortification in the United States. Int J Vitam Nutr Res 2017; р. 1–3.
13. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’srole. Adv Nutr 2012; 3 (1): 21–38.
14. Ahmed T, Fellus I, Gaudet J et al. Effect of folic acid on human trophoblast health and function in vitro. Placenta 2016; 37: 7–15.
15. Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57 (5): 142–9.
16. Practice Bulletin №187 Summary: neural tube defects. Obstet Gynecol 2017; 130 (6): 1394–6.
17. Демикова Н.С., Лапина А.С., Подольная М.А. и др. Динамика частоты врожденных пороков развития в РФ (по данным федеральной базы мониторинга ВПР за 2006–2012 гг.). Рос. вестн. перинатологии и педиатрии. 2015; 2: 72–7. / Demikova N.S., Lapina A.S., Podolnaia M.A. i dr. Dinamika chastoty vrozhdennykh porokov razvitiia v RF (po dannym federalnoi bazy monitoringa VPR za 2006–2012 gg.). Ros. vestn. perinatologii i pediatrii. 2015; 2: 72–7. [in Russian]
18. Wilson RD, Genetics Committee, Special Contributors. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Can 2015; 37 (6): 534–52.
19. Прегравидарная подготовка. Клинический протокол. Авт.-разраб. В.Е.Радзинский и др. М.: StatusPraesens, 2016. / Pregravidarnaia podgotovka. Klinicheskii protokol. Avt.-razrab. V.E.Radzinskii i dr. M.: StatusPraesens, 2016. [in Russian]
20. Громова О.А., Торшин И.Ю., Тетруашвили Н.К., Лисицына Е.Ю. Систематический анализ взаимосвязи дефицита витаминов и врожденных пороков развития. Consilium Medicum. 2012; 4 (6): 34–40. / Gromova O.A., Torshin I.Iu., Tetruashvili N.K., Lisitsyna E.Iu. Sistematicheskii analiz vzaimosviazi defitsita vitaminov i vrozhdennykh porokov razvitiia. Consilium Medicum. 2012; 4 (6): 34–40. [in Russian]
21. Shere M, Bapat P, Nickel C et al. Association between use of oral contraceptives and folate status: a systematic review and meta-analysis. J Obstet Gynaecol Can 2015; 37 (5): 430–8.
22. Michels KA, Wactawski-Wende J, Mills JL et al. Folate, homocysteine and the ovarian cycle among healthy regularly menstruating women. Hum Reprod 2017; 32 (8): 1743–50.
23. Micle O, Muresan M, Antal L et al. The influence of homocysteine and oxidative stress on pregnancy outcome. J Med Life 2012; 5 (1): 68–73.
24. Kim MW, Hong SC, Choi JS et al. Homocysteine, folate and pregnancy outcomes. J Obstet Gynaecol 2012; 32 (6): 520–4.
25. Gomes S, Lopes C, Pinto E. Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHO. Public Health Nutr 2016; 19 (1): 176–89.
26. Cawley S, McCartney D, Woodside JV et al. Optimization of folic acid supplementation in the prevention of neural tube defects. J Public Health (Oxf) 2017; р. 1–8.
27. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International active surveillance study of women taking oral contraceptives. Contraception 2014; 89 (4): 253–63.
28. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7.
29. Кулаков В.И., Прилепская В.Н., Радзинский В.Е. и соавт. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. М.: ГЭОТАР-Медиа, 2007. / Kulakov V.I., Prilepskaia V.N., Radzinskii V.E. i soavt. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. M.: GEOTAR-Media, 2007. [in Russian]
30. Юренева С.В., Прилепская В.Н., Ледина А.В. Предменструальный синдром и предменструальное дисфорическое расстройство. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. 3-е изд., перераб. М.: ГЭОТАР-Медиа, 2016; с. 895–907. / Iureneva S.V., Prilepskaia V.N., Ledina A.V. Predmenstrual'nyi sindrom i predmenstrual'noe disforicheskoe rasstroistvo. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. 3-e izd., pererab. M.: GEOTAR-Media, 2016; s. 895–907. [in Russian]
31. Тапильская Н.И., Глушакова Р.И. Пролонгированный режим комбинированного орального контрацептива: фокус на профилактику воспалительных заболеваний органов малого таза. Гинекология. 2017; 19 (1): 2–7. / Tapilskaia N.I., Glushakova R.I. Prolonged treatment of combined oral contraceptive: a focus on the prevention of inflammatory diseases of the pelvic organs. Gynecology. 2017; 19 (1): 2–7. [in Russian]
32. Касян В.Н. Комбинированные гормональные контрацептивы с фолатами: преимущество в лечении акне. Акушерство и гинекология. 2017; 10. / Kasian V.N. Kombinirovannye gormonalnye kontratseptivy s folatami: preimushchestvo v lechenii akne. Akusherstvo i ginekologiia. 2017; 10. [in Russian]
________________________________________________
2. Samtsov A.V. Klinicheskie osobennosti techeniia akne u zhenshchin. Vestn. dermatologii i venerologii. 2012; 6: 60–2. [in Russian]
3. Thiboutot D. Overview of acne and its treatment. Cutis 2008; 81 (S1): 3–7.
4. Monakhov S.A. Folate-containing antiandrogen oral contraceptives: dermatological aspects. Gynecology. 2016; 18 (4): 54–8. [in Russian]
5. Kuznetsova I.V., Konovalov V.A. Folic acid and its role in female reproduction. Gynecology. 2014; 16 (4): 17–23. [in Russian]
6. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–39.
7. Radzinskii V.E., Riabinkina T.S., Raevskaia O.A. Priem sinteticheskikh folatov: za i protiv. StatusPraesens. 2017; 5 (42). [in Russian]
8. Wang ZM, Zhou B, Nie ZL et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2012; 22 (10): 890–9.
9. Peng Y, Dong B, Wang Z. Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: A cohort study based on 1999–2010 National health and nutrition examination survey (NHANES). Int J Cardiol 2016; 219: 136–42.
10. Schroecksnadel K, Frick B, Fiegl M et al. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007; 45 (1): 47–53.
11. Tavani A, Malerba S, Pelucchi C et al. Diatary folates and cancer risk in a network of case-control studies. Ann Oncol 2012; 23 (10): 2737–42.
12. Ginsburg HJ, Mendez RV, Haskar-Zolnierek KB. Cautionaryote about magnitude of decline in neural tube birth defects following folic acid fortification in the United States. Int J Vitam Nutr Res 2017; р. 1–3.
13. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’srole. Adv Nutr 2012; 3 (1): 21–38.
14. Ahmed T, Fellus I, Gaudet J et al. Effect of folic acid on human trophoblast health and function in vitro. Placenta 2016; 37: 7–15.
15. Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57 (5): 142–9.
16. Practice Bulletin №187 Summary: neural tube defects. Obstet Gynecol 2017; 130 (6): 1394–6.
17. Demikova N.S., Lapina A.S., Podolnaia M.A. i dr. Dinamika chastoty vrozhdennykh porokov razvitiia v RF (po dannym federalnoi bazy monitoringa VPR za 2006–2012 gg.). Ros. vestn. perinatologii i pediatrii. 2015; 2: 72–7. [in Russian]
18. Wilson RD, Genetics Committee, Special Contributors. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Can 2015; 37 (6): 534–52.
19. Pregravidarnaia podgotovka. Klinicheskii protokol. Avt.-razrab. V.E.Radzinskii i dr. M.: StatusPraesens, 2016. [in Russian]
20. Gromova O.A., Torshin I.Iu., Tetruashvili N.K., Lisitsyna E.Iu. Sistematicheskii analiz vzaimosviazi defitsita vitaminov i vrozhdennykh porokov razvitiia. Consilium Medicum. 2012; 4 (6): 34–40. [in Russian]
21. Shere M, Bapat P, Nickel C et al. Association between use of oral contraceptives and folate status: a systematic review and meta-analysis. J Obstet Gynaecol Can 2015; 37 (5): 430–8.
22. Michels KA, Wactawski-Wende J, Mills JL et al. Folate, homocysteine and the ovarian cycle among healthy regularly menstruating women. Hum Reprod 2017; 32 (8): 1743–50.
23. Micle O, Muresan M, Antal L et al. The influence of homocysteine and oxidative stress on pregnancy outcome. J Med Life 2012; 5 (1): 68–73.
24. Kim MW, Hong SC, Choi JS et al. Homocysteine, folate and pregnancy outcomes. J Obstet Gynaecol 2012; 32 (6): 520–4.
25. Gomes S, Lopes C, Pinto E. Folate and folic acid in the periconceptional period: recommendations from official health organizations in thirty-six countries worldwide and WHO. Public Health Nutr 2016; 19 (1): 176–89.
26. Cawley S, McCartney D, Woodside JV et al. Optimization of folic acid supplementation in the prevention of neural tube defects. J Public Health (Oxf) 2017; р. 1–8.
27. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International active surveillance study of women taking oral contraceptives. Contraception 2014; 89 (4): 253–63.
28. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7.
29. Kulakov V.I., Prilepskaia V.N., Radzinskii V.E. i soavt. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. M.: GEOTAR-Media, 2007. [in Russian]
30. Iureneva S.V., Prilepskaia V.N., Ledina A.V. Predmenstrual'nyi sindrom i predmenstrual'noe disforicheskoe rasstroistvo. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. 3-e izd., pererab. M.: GEOTAR-Media, 2016; s. 895–907. [in Russian]
31. Tapilskaia N.I., Glushakova R.I. Prolonged treatment of combined oral contraceptive: a focus on the prevention of inflammatory diseases of the pelvic organs. Gynecology. 2017; 19 (1): 2–7. [in Russian]
32. Kasian V.N. Kombinirovannye gormonalnye kontratseptivy s folatami: preimushchestvo v lechenii akne. Akusherstvo i ginekologiia. 2017; 10. [in Russian]
Авторы
В.Н.Прилепская*, Е.Г.Назаренко
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*Vprilepskaya@mail.ru
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*Vprilepskaya@mail.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*Vprilepskaya@mail.ru
________________________________________________
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*Vprilepskaya@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.